Back to Search
Start Over
Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation.
- Source :
-
Blood [Blood] 2020 Nov 05; Vol. 136 (19), pp. 2237-2240. - Publication Year :
- 2020
- Subjects :
- Adolescent
Adult
Aged
Aged, 80 and over
Female
Follow-Up Studies
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy
Male
Middle Aged
Prognosis
Survival Rate
Young Adult
Antineoplastic Agents administration & dosage
Imatinib Mesylate administration & dosage
Leukemia, Myelogenous, Chronic, BCR-ABL Positive mortality
Leukemia, Myelogenous, Chronic, BCR-ABL Positive pathology
Tumor Burden drug effects
Withholding Treatment statistics & numerical data
Subjects
Details
- Language :
- English
- ISSN :
- 1528-0020
- Volume :
- 136
- Issue :
- 19
- Database :
- MEDLINE
- Journal :
- Blood
- Publication Type :
- Report
- Accession number :
- 32518953
- Full Text :
- https://doi.org/10.1182/blood.2019004371